NCT04130516 2025-12-18Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabLinnaeus Therapeutics, Inc.Phase 1/2 Recruiting200 enrolled